Please use this identifier to cite or link to this item:
Title: Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.
Austin Authors: Doecke, James D;Rembach, Alan;Villemagne, Victor L ;Varghese, Shiji;Rainey-Smith, Stephanie R;Sarros, Shannon;Evered, Lisbeth A;Fowler, Christopher J;Pertile, Kelly K;Rumble, Rebecca L;Trounson, Brett;Taddei, Kevin;Laws, Simon M;Macaulay, S Lance;Bush, Ashley I;Ellis, Kathryn A;Martins, Ralph;Ames, David;Silbert, Brendan;Vanderstichele, Hugo;Masters, Colin L ;Darby, David G;Li, Qiao-Xin;Collins, Steven
Affiliation: CSIRO Health and Biosecurity/Australian e-Health Research Centre, Brisbane, QLD, Australia
Cooperative Research Centre for Mental Health, Parkville, Victoria, Australia
The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Victoria, Australia
Department of Molecular Imaging and Therapy, Centre for PET, Austin Health, Heidelberg, Victoria, Australia
Department of Anaesthesia and Perioperative Pain Medicine, Centre for Anaesthesia and Cognitive Function, St Vincent's Hospital, Melbourne, Australia
Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital), Perth, WA, Australia
Academic Unit for Psychiatry of Old Age, The University of Melbourne, Melbourne, Australia
ADx NeuroSciences, Gent, Belgium
Department of Medicine (RMH), The University of Melbourne, Parkville, Australia
National Dementia Diagnostics Laboratory, The University of Melbourne, Victoria, Australia
Issue Date: 2018
Publication information: Journal of Alzheimer's disease : JAD 2018; 61(1): 169-183
Abstract: To enhance the accuracy of clinical diagnosis for Alzheimer's disease (AD), pre-mortem biomarkers have become increasingly important for diagnosis and for participant recruitment in disease-specific treatment trials. Cerebrospinal fluid (CSF) biomarkers provide a low-cost alternative to positron emission tomography (PET) imaging for in vivo quantification of different AD pathological hallmarks in the brains of affected subjects; however, consensus around the best platform, most informative biomarker and correlations across different methodologies are controversial. Assessing levels of Aβ-amyloid and tau species determined using three different versions of immunoassays, the current study explored the ability of CSF biomarkers to predict PET Aβ-amyloid (32 Aβ-amyloid-and 45 Aβ-amyloid+), as well as concordance between CSF biomarker levels and PET Aβ-amyloid imaging. Prediction and concordance analyses were performed using a sub-cohort of 77 individuals (48 healthy controls, 15 with mild cognitive impairment, and 14 with AD) from the Australian Imaging Biomarker and Lifestyle study of aging. Across all three platforms, the T-tau/Aβ42 ratio biomarker had modestly higher correlation with SUVR/BeCKeT (ρ= 0.69-0.8) as compared with Aβ42 alone (ρ= 0.66-0.75). Differences in CSF biomarker levels between the PET Aβ-amyloid-and Aβ-amyloid+ groups were strongest for the Aβ42/Aβ40 and T-tau/Aβ42 ratios (p < 0.0001); however, comparison of predictive models for PET Aβ-amyloid showed no difference between Aβ42 alone and the T-tau/Aβ42 ratio. This study confirms strong concordance between CSF biomarkers and PET Aβ-amyloid status is independent of immunoassay platform, supporting their utility as biomarkers in clinical practice for the diagnosis of AD and for participant enrichment in clinical trials.
DOI: 10.3233/JAD-170128
PubMed URL: 29171991
Type: Journal Article
Subjects: Amyloid
cerebrospinal fluid
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 5, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.